Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

Theresa J. Hydes, Sujan Ravi, Rohit Loomba, Meagan E. Gray

Clin Mol Hepatol. 2020;26(4):383-400. Published online July 17, 2020

Web of Science 49 Crossref 52

DOI: https://doi.org/10.3350/cmh.2020.0067

Liver graft from donation after circulatory death donor: Real practice to improve graft viability

Koji Hashimoto

Clin Mol Hepatol. 2020;26(4):401-410. Published online July 10, 2020

Web of Science 10 Crossref 10

DOI: https://doi.org/10.3350/cmh.2020.0072

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee

Clin Mol Hepatol. 2020;26(4):411-429. Published online August 28, 2020

Web of Science 66 Crossref 66

DOI: https://doi.org/10.3350/cmh.2020.0049

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

Web of Science 38 Crossref 41

DOI: https://doi.org/10.3350/cmh.2020.0137

Managing liver cirrhotic complications: Overview of esophageal and gastric varices

Cosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Gani

Clin Mol Hepatol. 2020;26(4):444-460. Published online October 1, 2020

Web of Science 61 Crossref 62

DOI: https://doi.org/10.3350/cmh.2020.0022

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

Web of Science 40 Crossref 39

DOI: https://doi.org/10.3350/cmh.2020.0136

Editorials

Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma

Sooyeon Oh, Jooho Lee

Clin Mol Hepatol. 2020;26(4):476-479. Published online October 1, 2020

Web of Science 12 Crossref 11

DOI: https://doi.org/10.3350/cmh.2020.0192

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

Web of Science 12 Crossref 11

DOI: https://doi.org/10.3350/cmh.2020.0208

Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma

Jaewhan Song

Clin Mol Hepatol. 2020;26(4):484-486. Published online October 1, 2020

Web of Science 9 Crossref 9

DOI: https://doi.org/10.3350/cmh.2020.0220

Acute-on-chronic liver failure: A predictor of poor prognosis in patients with variceal bleeding or a risk factor for variceal bleeding?

Nae-Yun Heo

Clin Mol Hepatol. 2020;26(4):487-488. Published online October 1, 2020

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2020.0209

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Paul Kwo, Deepti Dronamraju

Clin Mol Hepatol. 2020;26(4):489-491. Published online September 24, 2020

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2020.0228

Original Articles

The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma

Kanghyug Choi, Hee Yoon Jang, Joong Mo Ahn, Sung Ho Hwang, Jung Wha Chung, Yun Suk Choi, Jin-Wook Kim, Eun Sun Jang, Gwang Hyeon Choi, Sook-Hyang Jeong

Clin Mol Hepatol. 2020;26(4):492-505. Published online July 10, 2020

Web of Science 45 Crossref 44

DOI: https://doi.org/10.3350/cmh.2020.0005

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial

Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee

Clin Mol Hepatol. 2020;26(4):506-515. Published online July 10, 2020

Web of Science 48 Crossref 52

DOI: https://doi.org/10.3350/cmh.2020.0038

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients

Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik

Clin Mol Hepatol. 2020;26(4):516-528. Published online September 11, 2020

Web of Science 46 Crossref 44

DOI: https://doi.org/10.3350/cmh.2020.0016

Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway

Seulki Lee, Eun Ji Choi, Eun Ju Cho, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2020;26(4):529-539. Published online August 24, 2020

Web of Science 31 Crossref 31

DOI: https://doi.org/10.3350/cmh.2019.0056n

Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding

Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Hyung Joon Yim, Young Kul Jung, Jin Mo Yang, Do Seon Song, Young Seok Kim, Sang Gyune Kim, Dong Joon Kim, Ki Tae Suk, Eileen L. Yoon, Sang Soo Lee, Chang Wook Kim, Hee Yeon Kim, Jae Young Jang, Soung Won Jeong

Clin Mol Hepatol. 2020;26(4):540-553. Published online September 17, 2020

Web of Science 23 Crossref 23

DOI: https://doi.org/10.3350/cmh.2020.0034

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Desmond Y. H. Yap, Kevin S. H. Liu, Yu-Chun Hsu, Grace L. H. Wong, Ming-Chang Tsai, Chien-Hung Chen, Ching-Sheng Hsu, Yee Tak Hui, Michael K. K. Li, Chen-Hua Liu, Yee-Man Kan, Ming-Lung Yu, Man-Fung Yuen

Clin Mol Hepatol. 2020;26(4):554-561. Published online August 28, 2020

Web of Science 8 Crossref 8

DOI: https://doi.org/10.3350/cmh.2020.0058

Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea

Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park

Clin Mol Hepatol. 2020;26(4):562-576. Published online October 1, 2020

Web of Science 22 Crossref 23

DOI: https://doi.org/10.3350/cmh.2020.0126

Letters to the Editor

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Jeong Su Park, Soo Han Bae

Clin Mol Hepatol. 2020;26(4):577-578. Published online September 17, 2020

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2020.0143

How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma?

Bo Hyun Kim

Clin Mol Hepatol. 2020;26(4):579-581. Published online September 23, 2020

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2020.0200

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2020.0264

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Dong Joon Kim, Won-Il Jeong, Hidekazu Tsukamoto, Bin Gao

Clin Mol Hepatol. 2020;26(4):584-585. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0271

Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake

Seonghwan Hwang, Tianyi Ren, Bin Gao

Clin Mol Hepatol. 2020;26(4):586-594. Published online September 17, 2020

Web of Science 19 Crossref 18

DOI: https://doi.org/10.3350/cmh.2020.0100

From intestinal dysbiosis to alcohol-associated liver disease

Beatriz Garcia Mendes, Bernd Schnabl

Clin Mol Hepatol. 2020;26(4):595-605. Published online September 11, 2020

Web of Science 21 Crossref 24

DOI: https://doi.org/10.3350/cmh.2020.0086

Autophagy and liver cancer

Xiaojuan Chao, Hui Qian, Shaogui Wang, Sam Fulte, Wen-Xing Ding

Clin Mol Hepatol. 2020;26(4):606-617. Published online October 1, 2020

Web of Science 53 Crossref 45

DOI: https://doi.org/10.3350/cmh.2020.0169

Programmed cell death in alcohol-associated liver disease

Tatsunori Miyata, Laura E. Nagy

Clin Mol Hepatol. 2020;26(4):618-625. Published online September 21, 2020

Web of Science 45 Crossref 49

DOI: https://doi.org/10.3350/cmh.2020.0142

Inter-professional and inter-departmental alcoholism rehabilitation program

Masahiro Kikuchi, Naomi Matsutani, Ryota Ishihara, Masako Sugihara, Yuuki Mizuno, Chiyo Chiba, Takahiro Ohta, Eri Yamada, Sota Oguro, Yasuko Sato, Hiroki Bessho, Yoshinori Horie

Clin Mol Hepatol. 2020;26(4):626-632. Published online October 1, 2020

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2020.0151

The lymphatic system in alcohol-associated liver disease

Reiichiro Kondo, Yasuko Iwakiri

Clin Mol Hepatol. 2020;26(4):633-638. Published online September 21, 2020

Web of Science 3 Crossref 3

DOI: https://doi.org/10.3350/cmh.2020.0179

Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Shiv Kumar Sarin, Shvetank Sharma

Clin Mol Hepatol. 2020;26(4):639-651. Published online October 1, 2020

Web of Science 11 Crossref 12

DOI: https://doi.org/10.3350/cmh.2020.0196

Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies

Seung Ha Park, Dong Joon Kim

Clin Mol Hepatol. 2020;26(4):652-661. Published online October 1, 2020

Web of Science 24 Crossref 29

DOI: https://doi.org/10.3350/cmh.2020.0160

The effect of moderate alcohol drinking in nonalcoholic fatty liver disease

Jong Hwa Choi, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2020;26(4):662-669. Published online September 25, 2020

Web of Science 40 Crossref 40

DOI: https://doi.org/10.3350/cmh.2020.0163

Liver-lung axes in alcohol-related liver disease

Gavin E. Arteel

Clin Mol Hepatol. 2020;26(4):670-676. Published online October 1, 2020

Web of Science 11 Crossref 10

DOI: https://doi.org/10.3350/cmh.2020.0174

Roles of the complement system in alcohol-induced liver disease

Yi Zhou, Guandou Yuan, Fudi Zhong, Songqing He

Clin Mol Hepatol. 2020;26(4):677-685. Published online October 1, 2020

Web of Science 12 Crossref 14

DOI: https://doi.org/10.3350/cmh.2020.0094

Emerging medical therapies for severe alcoholic hepatitis

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

Web of Science 16 Crossref 17

DOI: https://doi.org/10.3350/cmh.2020.0145

Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell

Hee-Hoon Kim, Sung Eun Choi, Won-Il Jeong

Clin Mol Hepatol. 2020;26(4):697-704. Published online October 1, 2020

Web of Science 10 Crossref 8

DOI: https://doi.org/10.3350/cmh.2020.0152

Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease

Sen Han, Ting Zhang, Praveen Kusumanchi, Nazmul Huda, Yanchao Jiang, Zhihong Yang, Suthat Liangpunsakul

Clin Mol Hepatol. 2020;26(4):705-714. Published online October 1, 2020

Web of Science 11 Crossref 10

DOI: https://doi.org/10.3350/cmh.2020.0166

Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases

Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2020;26(4):715-727. Published online September 22, 2020

Web of Science 33 Crossref 34

DOI: https://doi.org/10.3350/cmh.2020.0173

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

Web of Science 27 Crossref 26

DOI: https://doi.org/10.3350/cmh.2020.0202

Alcohol and hepatocarcinogenesis

Makiko Taniai

Clin Mol Hepatol. 2020;26(4):736-741. Published online October 1, 2020

Web of Science 32 Crossref 30

DOI: https://doi.org/10.3350/cmh.2020.0203

Hepatic Hippo signaling inhibits development of hepatocellular carcinoma

Yuchen Liu, Xiaohui Wang, Yingzi Yang

Clin Mol Hepatol. 2020;26(4):742-750. Published online September 28, 2020

Web of Science 41 Crossref 40

DOI: https://doi.org/10.3350/cmh.2020.0178

Viewed By 6029	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5559	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 5356	MAFLD: How is it different from NAFLD?
Viewed By 5326	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4904	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 208	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 146	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 109	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues